Einzeltreffer — DigiBib

Rationale: Varenicline, a partial agonist at α4β2 nicotinic receptors (nAChRs) aids smoking cessation by reducing craving. Successful quitting may be associated with greater inhibitory control but the effectiveness of varenicline in this regard is unknown.

Objectives: This study aimed to investigate the effect of varenicline on aspects of inhibitory control in smokers.

Methods: A double-blind, placebo-controlled study investigating the effect of varenicline 1 mg (or matched placebo) in satiated and abstinent smokers. Tests included Rapid Visual Information Processing (RVIP), Stop-Signal (SS), Prospective Memory (PM) and the Cambridge Gambling Task (CGT).

Results: Smoking enhanced RVIP accuracy and latency to respond. Varenicline did not alter RVIP performance, nor the effect of smoking, suggesting that these effects were unrelated to α4β2 nAChRs. Smoking increased the number of errors during SS and increased the stop latency, indicating that smoking decreased inhibitory control. Varenicline partially mimicked this effect of smoking but also reduced the smoking-induced increase, indicating a role for α4β2 nAChRs. Likewise, smoking increased the number of points bet following a win during CGT and varenicline blocked this effect. There was no effect of smoking or varenicline on PM target detection per se. However, smoking protected the target detection rate in the ongoing task when a concurrent intention was introduced. Varenicline improved response speed in both satiated and abstinent smokers.

Conclusions: Some aspects of inhibitory control may be mediated by α4β2-related mechanisms and blockade of smoking-induced disinhibition may contribute towards the action of varenicline as an aid to smoking cessation.

Titel:	Effect of varenicline on aspects of inhibitory control in smokers.
Autor/in / Beteiligte Person:	Austin, AJ ; Duka, T ; Rusted, J ; Jackson, A
Link:	Volltext (PDF) View record at Springer (Volltext)
Zeitschrift:	Psychopharmacology, Jg. 231 (2014-09-01), Heft 18, S. 3771-85
Veröffentlichung:	Berlin, New York, Springer-Verlag., 2014
Medientyp:	academicJournal
ISSN:	1432-2072 (electronic)
DOI:	10.1007/s00213-014-3512-7
Schlagwort:	Adult Benzazepines therapeutic use Double-Blind Method Female Humans Male Neuropsychological Tests Nicotinic Agonists therapeutic use Prospective Studies Quinoxalines therapeutic use Smoking drug therapy Smoking Cessation psychology Tobacco Use Disorder drug therapy Varenicline Young Adult Benzazepines pharmacology Executive Function drug effects Inhibition, Psychological Nicotinic Agonists pharmacology Quinoxalines pharmacology Reaction Time drug effects Smoking Cessation methods
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Language: English [Psychopharmacology (Berl)] 2014 Sep; Vol. 231 (18), pp. 3771-85. <i>Date of Electronic Publication: </i>2014 Mar 21. MeSH Terms: Inhibition, Psychological* ; Benzazepines / pharmacology ; Executive Function / drug effects ; Nicotinic Agonists / pharmacology ; Quinoxalines / pharmacology ; Reaction Time / drug effects ; Smoking Cessation / methods ; Adult ; Benzazepines / therapeutic use ; Double-Blind Method ; Female ; Humans ; Male ; Neuropsychological Tests ; Nicotinic Agonists / therapeutic use ; Prospective Studies ; Quinoxalines / therapeutic use ; Smoking / drug therapy ; Smoking Cessation / psychology ; Tobacco Use Disorder / drug therapy ; Varenicline ; Young Adult References: Nicotine Tob Res. 2001 Feb;3(1):7-16. (PMID: 11260806) ; Psychopharmacology (Berl). 2008 Apr;197(3):371-7. (PMID: 18084743) ; J Med Chem. 2005 May 19;48(10):3474-7. (PMID: 15887955) ; Addiction. 2002 Sep;97(9):1163-70. (PMID: 12199832) ; Psychopharmacology (Berl). 1998 Aug;138(3-4):362-8. (PMID: 9725759) ; Nat Neurosci. 2001 Jan;4(1):95-102. (PMID: 11135651) ; Psychopharmacology (Berl). 1993;110(3):333-6. (PMID: 7831427) ; Psychopharmacology (Berl). 2009 Jan;202(1-3):93-102. (PMID: 18815772) ; Psychopharmacology (Berl). 2000 Apr;149(3):293-305. (PMID: 10823411) ; Addiction. 1998 Mar;93(3):317-20. (PMID: 10328040) ; Psychopharmacology (Berl). 1999 Feb;142(2):158-64. (PMID: 10102768) ; Psychopharmacology (Berl). 1988;94(4):563-5. (PMID: 3131804) ; Psychopharmacology (Berl). 1984;82(3):147-50. (PMID: 6425892) ; J Subst Abuse. 1989;1(4):407-16. (PMID: 2485288) ; Addict Behav. 1989;14(5):577-80. (PMID: 2589137) ; Psychopharmacology (Berl). 2007 Mar;190(4):457-67. (PMID: 17205318) ; Psychol Bull. 2000 Mar;126(2):220-46. (PMID: 10748641) ; Synapse. 2000 Dec 15;38(4):375-83. (PMID: 11044884) ; Psychopharmacology (Berl). 2001 Jan 1;153(2):249-57. (PMID: 11205427) ; Exp Clin Psychopharmacol. 2012 Aug;20(4):278-86. (PMID: 22708609) ; Psychopharmacology (Berl). 2011 Oct;217(4):455-73. (PMID: 21503608) ; Psychopharmacology (Berl). 2009 Nov;207(1):153-62. (PMID: 19693492) ; Psychopharmacology (Berl). 2012 Sep;223(2):131-8. (PMID: 22526531) ; Alcohol Clin Exp Res. 2005 Mar;29(3):317-25. (PMID: 15770105) ; Neuropsychopharmacology. 2008 Feb;33(3):627-33. (PMID: 17460613) ; Int J Neuropsychopharmacol. 2008 May;11(3):401-11. (PMID: 18042304) ; NIDA Res Monogr. 1979 Jan;(23):158-84. (PMID: 111135) ; Drug Alcohol Depend. 2008 Apr 1;94(1-3):82-91. (PMID: 18063322) ; Neurotoxicol Teratol. 2000 Jul-Aug;22(4):487-502. (PMID: 10974587) ; Eur J Neurosci. 2009 Feb;29(3):539-50. (PMID: 19187266) ; Biol Psychiatry. 2002 Jan 15;51(2):151-63. (PMID: 11822994) ; Clin Pharmacol Ther. 2008 Apr;83(4):607-14. (PMID: 18288085) ; Biol Psychiatry. 2011 Jun 15;69(12):e55-68. (PMID: 20932513) ; Psychopharmacology (Berl). 2000 Jan;148(1):33-40. (PMID: 10663415) ; Drug Alcohol Depend. 1989 Jun;23(3):259-66. (PMID: 2752917) ; J Exp Psychol Hum Percept Perform. 1984 Apr;10(2):276-91. (PMID: 6232345) ; J Neurosci. 2011 Jul 27;31(30):10891-902. (PMID: 21795541) ; J Neurophysiol. 2000 Dec;84(6):3072-7. (PMID: 11110834) ; Behav Brain Res. 2000 Dec 20;117(1-2):197-208. (PMID: 11099773) ; Br J Addict. 1991 Sep;86(9):1119-27. (PMID: 1932883) ; Psychopharmacology (Berl). 2005 Nov;182(3):355-65. (PMID: 16160879) ; Pharmacol Biochem Behav. 2005 Nov;82(3):539-48. (PMID: 16360813) ; Nicotine Tob Res. 2013 Jan;15(1):277-81. (PMID: 22573728) ; Neuropsychobiology. 1989;21(2):76-83. (PMID: 2693994) ; Neuropsychopharmacology. 2009 Jan;34(2):257-65. (PMID: 18418361) ; Neuropsychopharmacology. 2006 Jul;31(7):1545-9. (PMID: 16319914) ; J Neurosci. 2004 Dec 15;24(50):11244-52. (PMID: 15601930) ; Nicotine Tob Res. 2004 Apr;6(2):327-48. (PMID: 15203807) ; J Neurosci. 2012 Jun 13;32(24):8401-12. (PMID: 22699920) ; Nicotine Tob Res. 2000 Feb;2(1):19-37. (PMID: 11072438) ; Psychol Rep. 1978 Dec;43(3 Pt 1):803-6. (PMID: 740823) ; Biol Psychol. 2011 Sep;88(1):83-93. (PMID: 21742012) ; J Pharmacol Exp Ther. 2001 May;297(2):646-56. (PMID: 11303054) ; Psychopharmacology (Berl). 1996 Sep;127(1):31-8. (PMID: 8880941) ; Psychopharmacology (Berl). 2011 Jul;216(1):29-42. (PMID: 21301814) ; Mol Pharmacol. 2000 Aug;58(2):312-8. (PMID: 10908298) ; Perspect Psychol Sci. 2009 Mar;4(2):162-76. (PMID: 26158943) ; Psychopharmacology (Berl). 2001 Jul;156(2-3):360-7. (PMID: 11549236) ; Clin Pharmacol Ther. 2010 Jul;88(1):109-14. (PMID: 20485335) ; Psychopharmacology (Berl). 1999 Oct;146(4):447-54. (PMID: 10550495) ; Neuropsychopharmacology. 2013 Feb;38(3):476-84. (PMID: 23072834) ; J Neurosci. 1999 Oct 15;19(20):9029-38. (PMID: 10516320) ; J Gen Psychol. 1982 Jan;106(1st Half):77-83. (PMID: 7057167) ; Pharmacol Biochem Behav. 2008 Nov;91(1):165-9. (PMID: 18675291) ; Psychopharmacology (Berl). 1986;89(1):55-9. (PMID: 3090592) ; Psychopharmacology (Berl). 2012 Mar;220(2):331-40. (PMID: 21969123) ; Biol Psychiatry. 2009 Jan 15;65(2):144-9. (PMID: 18842256) ; Addiction. 2009 May;104(5):850-8. (PMID: 19344444) ; Neuropharmacology. 2007 Mar;52(3):985-94. (PMID: 17157884) ; Psychopharmacology (Berl). 1976 Oct 20;50(1):35-9. (PMID: 827760) ; Psychopharmacology (Berl). 2010 May;209(4):351-9. (PMID: 20238211) ; Psychopharmacology (Berl). 2002 Jul;162(2):129-37. (PMID: 12110990) ; Mol Pharmacol. 2006 Sep;70(3):801-5. (PMID: 16766716) ; Psychopharmacology (Berl). 1994 Jan;113(3-4):445-52. (PMID: 7862857) ; Neuropsychopharmacology. 2010 Apr;35(5):1090-6. (PMID: 20072115) Substance Nomenclature: 0 (Benzazepines) ; 0 (Nicotinic Agonists) ; 0 (Quinoxalines) ; W6HS99O8ZO (Varenicline) Entry Date(s): Date Created: 20140322 Date Completed: 20150910 Latest Revision: 20211021 Update Code: 20240513

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Effect of varenicline on aspects of inhibitory control in smokers.